Welkin’s software will streamline workflows for care teams and enable personalized, ongoing support for patients receiving therapy for urinary and fecal dysfunction
April 08, 2019 09:00 AM Eastern Daylight Time
Welkin Health, a privately-held patient relationship management software company today announced it is partnering with Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a company focused on the design, development, and commercialization of Sacral Neuromodulation (“SNM”) solutions. The companies will launch a program designed to support care teams and patients implanted with the Axonics r-SNM™ System, the first-ever long-lived rechargeable neurostimulator for patients suffering from overactive bladder and fecal incontinence.
Welkin’s patient management software enables Axonics commercial and clinical support teams to capture and utilize relevant data to support patients and physicians.
Chase Hensel, CEO of Welkin Health said, “The program we’re building with Axonics prioritizes the patient experience. This means the Axonics teams will have the pieces in place to easily manage complex data and guide workflows. We believe that having this tool in place will allow many more patients to benefit from SNM therapy and Axonics’ innovative long-lived technology.”
“We selected to work with Welkin given their software has the ability to seamlessly follow our patients during their journey from intake, through implant and post-operative programming and follow up such that patients feel supported,” commented Raymond W. Cohen, CEO of Axonics. “The Welkin system promises to create efficiencies in our operations allowing us to deploy our field personnel where and when they are needed to support cases.”
About Welkin Health
Welkin builds patient management software that guides teams to better care. Welkin configures patient programs into workflows that keep patients and teams on track. Welkin’s software makes engagement seamless and patient-centered, enabling health workers to build strong patient relationships for long-term positive outcomes.
About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, CA, is focused on the development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction. The Axonics r-SNM System is the first rechargeable Sacral Neuromodulation system approved for sale in Europe, Canada and Australia, and the first SNM system to gain CE mark for full-body MRI conditional labeling. Premarket Approval (PMA) for the r-SNM System is currently pending with the U.S. FDA. For more information, visit the Company’s website at www.axonicsmodulation.com.